Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
By Adria Calatayud
Roche Holding said a drug candidate showed better potential than existing therapies in a late-stage study with patients with a type of advanced lung cancer who had been previously treated.
The Swiss drugmaker said Thursday that its experimental drug, divarasib, met its primary and key secondary objectives in a head-to-head clinical trial that compared it against approved treatments Amgen's Lumakras and Mirati Therapeutics's Krazati.
Divarasib showed meaningful improvements in both patients' overall survival and the time they survived without the disease worsening, Roche said. No new safety signals were identified, it added.
Roche said it would submit the data to health authorities with the aim of launching the treatment as soon as possible.
The company is evaluating divarasib on its own and as part of drug combinations without chemotherapy across different settings of the disease and stages of treatment, it said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
July 02, 2026 01:40 ET (05:40 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States